Loading
BRCA Gene Mutations in Cancer / Ovarian Cancer Diagnosis and Treatment · Journal article
Frontiers in Oncology · September 8, 2026
A consensus or society position rather than new primary data.
This narrative literature review synthesizes evidence that BRCA1/2 mutation status serves as a key prognostic and predictive biomarker in ovarian cancer, with carriers showing improved progression-free and overall survival, primarily through enhanced platinum sensitivity and PARP inhibitor response. The review recommends universal BRCA testing and personalized treatment selection, but is not a formal systematic review or meta-analysis with pooled effect estimates.
Narrative literature review. Peer-reviewed publications on BRCA1/2 mutations and ovarian cancer treatment and prognosis; language restricted to English..
BRCA1/2 mutation carriers experience improved progression-free survival and, in many studies, prolonged overall survival compared with non-carriers Survival advantage attributed to increased sensitivity to platinum-based chemotherapy and efficacy of PARP inhibitors in homologous recombination-deficient tumors Universal BRCA testing recommended to optimize treatment selection and identify candidates for maintenance PARP inhibitor therapy
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should implement universal BRCA1/2 testing in ovarian cancer management to guide platinum and PARP inhibitor therapy selection, and counsel patients on implications for treatment response and outcomes. Further research is needed to overcome PARP inhibitor resistance.
A literature review synthesizing evidence on BRCA1/2 as prognostic and predictive biomarkers in ovarian cancer, providing clinical recommendations for testing and treatment selection rather than reporting original trial data.
As stated by the source record.
Clinicians should implement universal BRCA1/2 testing in ovarian cancer management to guide platinum and PARP inhibitor therapy selection, and counsel patients on implications for treatment response and outcomes. Further research is needed to overcome PARP inhibitor resistance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Introduction Ovarian cancer remains one of the leading causes of cancer-related mortality among women because of its asymptomatic early course, delayed diagnosis, and frequent presentation at advanced stages. Germline and somatic mutations in the BRCA1 and BRCA2 genes significantly increase the risk of ovarian cancer by impairing homologous recombination DNA repair, resulting in genomic instability. Beyond their role in carcinogenesis, BRCA mutations have become important prognostic and predictive biomarkers, influencing treatment response and clinical outcomes. This review summarizes current evidence regarding the impact of BRCA1/2 status on prognosis and therapeutic strategies in ovarian cancer. Methods A literature review was conducted using the PubMed and Scopus databases. English-language articles published between 2016 and 2026 were identified using combinations of the keywords ovarian cancer, BRCA1, BRCA2, PARP inhibitors, homologous recombination deficiency, and treatment. Original studies, systematic reviews, meta-analyses, and relevant clinical trials were included. Results The available evidence demonstrates that patients carrying BRCA1 or BRCA2 mutations generally experience improved progression-free survival and, in many studies, prolonged overall survival compared with non-carriers. This survival advantage is largely attributed to increased sensitivity to platinum-based chemotherapy and the efficacy of PARP inhibitors, which exploit synthetic lethality in homologous recombination-deficient tumors. The literature also emphasizes the importance of universal BRCA testing to optimize treatment selection, identify candidates for maintenance PARP inhibitor therapy, and facilitate genetic counseling. In addition, emerging mechanisms of resistance to PARP inhibitors remain a significant therapeutic challenge. Conclusion BRCA1/2 mutation status is a key biomarker in the management of ovarian cancer, supporting personalized treatment strategies and improving patient outcomes. Further research is needed to identify novel predictive biomarkers, overcome therapeutic resistance, and develop more effective targeted therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.